AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Phase III Insulin Add-On Asia Regional Program - ST
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2017-08-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 477
- Registration Number
- NCT02096705
- Locations
- 🇸🇬
Local Institution, Singapore, Singapore
Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD9291 in Volunteers
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2015-10-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 8
- Registration Number
- NCT02096679
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Solid Tumours
- Interventions
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2015-06-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 26
- Registration Number
- NCT02093728
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer
Phase 1
Completed
- Conditions
- Solid Tumours
- Interventions
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 79
- Registration Number
- NCT02093351
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 210
- Registration Number
- NCT02094261
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study
Phase 2
Terminated
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2014-03-20
- Last Posted Date
- 2014-06-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 198
- Registration Number
- NCT02092961
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2017-04-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 882
- Registration Number
- NCT02091986
- Locations
- 🇸🇰
Research Site, Presov, Slovakia
Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea
- First Posted Date
- 2014-03-18
- Last Posted Date
- 2015-08-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1711
- Registration Number
- NCT02090673
- Locations
- 🇰🇷
Local Institution, Seoul, Korea, Republic of
A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
- First Posted Date
- 2014-03-14
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 446
- Registration Number
- NCT02087423
- Locations
- 🇬🇧
Research Site, Stoke-on-Trent, United Kingdom
Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer
Phase 2
Terminated
- Conditions
- Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2014-03-14
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 22
- Registration Number
- NCT02087241
- Locations
- 🇺🇸
Research Site, Nashville, Tennessee, United States